Skip to main content

Advertisement

Table 1 Clinical characteristics of cohorts studied

From: Overcoming intratumoural heterogeneity for reproducible molecular risk stratification: a case study in advanced kidney cancer

Cohort Total Development (SuMR) Validation (SCOTRRCC)
Number of patients 44 22 22
Age, median (range)a 66.5 (38.2–79.3) 64.5 (44–78) 67.5 (38.2–79.3)
Overall survival (months):b
 Median 16.2 23.5 12.3
 Interquartile range 9.1–25.9 14.8–29.8 7.6–18.8
 Number censored 22 10 12
 Modes (bimodal model) 10.6, 27.3 10.2, 27.4 11.6, 27.5
Number of samples per tumoura median (range) 4 (1–10) 4 (1–10) 4 (2–8)
Male genderb 29 15 14
Fuhrman grade:b
 4 9 1 8
 3 22 12 10
 2 13 9 4
Stage:b
 T4 4 4 0
 T3 33 13 20
 T2 6 4 2
 T1 1 1 0
Performance status:c
 KPS >80 (unavailable) 34 (1) 13 (0) 21 (1)
Anaemiab ,+ (unavailable) 22 (2) 12 (0) 10 (2)
Raised calciumb (unavailable) 8 (7) 5 (0) 3 (7)
Raised LDHc (unavailable) 10 (15) 5 (0) 5 (15)
Neutrophil count >70% upper limit of normalb (unavailable) 9 (2) 2 (0) 7 (2)
Platelet count >400b (unavailable) 12 (2) 6 (0) 6 (2)
VHL mutationb 31 14 17
Renal response at surgery:
 Partial response 2
 Stable disease 20
Number of metastatic sites:b
 1 19 6 13
 2 18 11 7
 3 7 5 2
IMDC class:b
 Intermediate 26 12 14
 Poor 16 10 6
 Unavailable 2 0 2
MSKCC class:b
 Favourable/intermediate: 26 13 13
 Poor 12 9 3
 Unavailable 6 0 6
  1. +Hb <130 (M), <110 (F); a p < 0.05; b p > 0.05; c p < 10-4